News | September 18, 2009

Accumetrics Reviews Meta-analysis Anti-Platelet Therapy After PCI at TCT

September 18, 2009 – Patients’ response to anti-platelet therapy after percutaneous coronary intervention (PCI) and its impact on clinical outcomes will be covered in a TCT 2009 breakfast symposium starting at 6:30 a.m. Wedensday, Sept. 23 in room 121 at the Moscone Center in San Francisco.

The session will help participants gain an understanding of the landscape of oral antiplatelet therapy in 2010 and review options of assessing response in antiplatelet therapy, and review the impact of platelet reactivity on clinical outcomes via a comprehensive meta-analysis.

The presentation includes:

• 7 a.m. – “Landscape of Oral Antiplatelet Therapy 2010,” presented by George Dangas, M.D., Ph.D.

• 7:10 a.m. – “Impact of Platelet Reactivity on Clinical Outcomes: A Meta-Analysis,” presented by
Somjot Brar, M.D.

• 7:25 a.m. – Case reviews and discussion moderator - George Dangas. Discussants include Germano Di Sciascio, Franz-Josef Neumann, M.D., Somjot Brar

• 7:50 a.m. – Discussion with audience questions

• 8 a.m. – Adjourn

The sponsor of the event is Accumetrics, maker of the VerifyNow System, which offers physician’s high level clinical data regarding their patient’s anti-platelet medications within minutes with an in-office test. The VerifyNow System assesses response to life-saving anti-platelet therapies, such as aspirin, Plavix, Effient and GP IIb/IIIa inhibitors. Patients respond to anti-platelet medications differently and these tests help physicians ensure their patients are receiving the optimal treatment.

For more information:

Related Content

Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
Overlay Init